VKORC1 , CYP2C9 and CYP4F2 Genetic-based Algorithm for Warfarin Dosing: An Italian Retrospective Study
- 22 December 2010
- journal article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 12 (1) , 15-25
Abstract
Aim: A total of 371 patients under stable warfarin therapy were retrospectively selected to develop a pharmacogenetic algorithm to identify the individual maintenance dose. Materials & methods: The variables that were entered into the algorithm were: VKORC1, CYP2C9 and CYP4F2 polymorphisms, body surface area and age. Results: The percentage of cases whose predicted mean weekly warfarin dose was within 20% of the actual maintenance dose was 51.8% considering patients overall, and were 36.2, 66.2 and 55.4%, respectively, taking into account patients requiring low (≤25 mg/week), intermediate (25–45 mg/week) and high (≥45 mg/week) doses. The algorithm could correctly assign 73.8 and 63.2% of patients to the low- and high-dose regimens, respectively. We developed and validated a pharmacogenetic algorithm in a series of Italian patients, we then tested, in the same series of italian patients, the formulas of three published algorithms. These three algorithms were developed and validated by their authors in a se...Keywords
This publication has 40 references indexed in Scilit:
- Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groupsBlood, 2010
- CYP4F2 Is a Vitamin K1 Oxidase: An Explanation for Altered Warfarin Dose in Carriers of the V433M VariantMolecular Pharmacology, 2009
- A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin DosePLOS Genetics, 2009
- Estimation of the Warfarin Dose with Clinical and Pharmacogenetic DataNew England Journal of Medicine, 2009
- The largest prospective warfarin-treated cohort supports genetic forecastingBlood, 2009
- VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–AmericansPharmacogenomics, 2008
- Warfarin PharmacogeneticsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirementBlood, 2008
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Association of warfarin dose with genes involved in its action and metabolismHuman Genetics, 2006